Literature DB >> 464417

The chronic sequelae of non-A, non-B hepatitis.

M Berman, H J Alter, K G Ishak, R H Purcell, E A Jones.   

Abstract

Twenty-six of 388 patients (6.7%) followed prospectively after open-heart surgery developed non-A, non-B hepatitis. Of these 26, 12 had an elevated (often fluctuating) serum alanine aminotransferase (SGPT) for greater than 1 year. Liver biopsy, done in eight of 12, showed chronic active hepatitis in six and chronic persistent hepatitis in two; one patient with chronic active hepatitis had early cirrhosis. Anicteric patients with peak SGPT greater then 300 IU/L were at greatest risk of developing chronic hepatitis. Chronic non-A, non-B hepatitis was symptomatically mild and unaccompanied by physical signs or laboratory evidence of autoimmune disease or severe chronic liver disease. In all 12 patients there was spontaneous improvement in serum transaminase over a period of 1 to 3 years, and four patients had sustained normalization of SGPT. Thus chronic active hepatitis is a common sequela of acute non-A, non-B hepatitis but may have a better prognosis than chronic active hepatitis of other causes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464417     DOI: 10.7326/0003-4819-91-1-1

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  38 in total

Review 1.  Blood transfusion and hepatitis: still a threat?

Authors:  H W Reesink; C L van der Poel
Journal:  Blut       Date:  1989-01

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Biophysical properties and morphology of purified antigen associated with non-A, non-B hepatitis.

Authors:  O Spertini; P C Frei
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

Review 4.  The hazards of blood transfusion in historical perspective.

Authors:  Harvey J Alter; Harvey G Klein
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

5.  Hepatitis C virus infection. Define seropositivity.

Authors:  J Craske; W K Paver
Journal:  BMJ       Date:  1994-06-25

Review 6.  Viral hepatitis and the anaesthetist.

Authors:  R A Browne; M A Chernesky
Journal:  Can Anaesth Soc J       Date:  1984-05

7.  Cloning of serum RNA associated with hepatitis C infection suggesting heterogeneity of the agent(s) responsible for the infection.

Authors:  T Arima; C Mori; A Takamizawa; T Nakajima; K Kanai
Journal:  Gastroenterol Jpn       Date:  1989-12

8.  Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland.

Authors:  P J Conlon; J J Walshe; E G Smyth; E B McNamara; J Donohoe; M Carmody
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

9.  Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

Authors:  N C Tassopoulos; M G Koutelou; G Papatheodoridis; H Polychronaki; I Delladetsima; T Giannikakis; A Todoulos; A Toliopoulos; A Hatzakis
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 10.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.